MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 26.02.2026
Amphastar Pharmaceuticals Gesamtverbindlichkeiten 2011-2026 | AMPH
Gesamtverbindlichkeiten Jährlich Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 840 M | 845 M | 873 M | 213 M | 226 M | 183 M | 159 M | 149 M | 117 M | 98.5 M | 94.6 M | 108 M | 87.2 M | 84 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 873 M | 84 M | 291 M |
Gesamtverbindlichkeiten Vierteljährlich Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 889 M | 858 M | 875 M | 845 M | 818 M | 778 M | - | 873 M | 949 M | - | 225 M | 213 M | - | 224 M | 237 M | 226 M | 222 M | 199 M | 195 M | 183 M | 183 M | 183 M | 183 M | 159 M | 159 M | 159 M | 159 M | 149 M | 149 M | 149 M | 149 M | 117 M | 117 M | 117 M | 117 M | 98.5 M | 98.5 M | 98.5 M | 98.5 M | 94.6 M | 94.6 M | 94.6 M | 94.6 M | 108 M | 108 M | 108 M | 108 M | 87.2 M | 87.2 M | 87.2 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 949 M | 87.2 M | 266 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 95.5 | -3.88 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
157 M | $ 2.59 | -4.78 % | $ 494 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
Cardiff Oncology
CRDF
|
16.5 M | $ 1.61 | -2.42 % | $ 108 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Cue Biopharma
CUE
|
15.8 M | $ 34.94 | 17.05 % | $ 3.31 B | USA |
 |
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Editas Medicine
EDIT
|
159 M | $ 3.04 | 1.33 % | $ 270 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
5.68 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Exelixis
EXEL
|
683 M | $ 44.42 | 0.57 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Galapagos NV
GLPG
|
171 M | $ 28.39 | -0.13 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.27 | 0.49 % | $ 6.83 B |  Spain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.5 | 5.42 % | $ 5.76 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
31.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
ImmuCell Corporation
ICCC
|
15.5 M | $ 8.87 | 1.66 % | $ 80.1 M | USA |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 1.97 | -7.51 % | $ 152 M | Germany |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |